Are Chinese Peptide Purity Standards Changing? What Recent Investigations Reveal About 99% Purity Claims

New reporting from the Los Angeles Times and published scientific research raises important questions about peptide manufacturing, quality documentation, and independent laboratory verification.

Published by NuRev Sales Research Team · Research & Analytical Insights · October 19, 2026

The global peptide supply chain is facing increasing scrutiny as researchers, regulators, and independent laboratories examine the quality of materials distributed through international manufacturing networks.

One question circulating within the research peptide industry is particularly concerning:

Are Chinese manufacturers deliberately lowering peptide purity below the commonly advertised 99% threshold?

At present, there is no verified official announcement establishing a nationwide Chinese policy to reduce peptide purity standards for materials exported to the United States.

However, recent investigations have documented serious manufacturing deficiencies at specific facilities, while peer-reviewed research has identified significant discrepancies between advertised purity claims and measured product composition in certain online peptide samples.

These developments raise broader questions about manufacturing oversight, analytical transparency, and the reliability of certificates of analysis.

Los Angeles Times Reports Serious Manufacturing Problems at Chinese GLP-1 Suppliers

On October 19, 2026, the Los Angeles Times published an article, based on Bloomberg reporting, titled Black Mold, Bugs Found at Chinese Plants Making GLP-1 Compounding Agents.

The report described FDA inspection findings at two Chinese facilities manufacturing or handling active pharmaceutical ingredients associated with semaglutide and tirzepatide.

According to the reporting, inspectors documented serious deficiencies, including contamination concerns, questionable documentation practices, and failures involving supplier verification.

At one facility, inspectors reportedly observed mold, insect activity, and employees attempting to conceal or dispose of records and samples.

At another, investigators identified concerns involving the relabeling of ingredients obtained from other manufacturers without adequate review of supporting quality information.

The FDA subsequently placed the companies on an import-alert list, allowing their products to be detained at the U.S. border.

These findings highlight the importance of manufacturing oversight and reliable documentation.

However, the inspection findings do not establish that all Chinese peptide manufacturers operate under similar conditions, nor do they demonstrate a coordinated decision to reduce peptide purity.

Source: Los Angeles Times/Bloomberg, October 19, 2026.

A Published Study Found Major Discrepancies in Online Semaglutide Products

Concerns about peptide quality extend beyond manufacturing inspections.

A peer-reviewed study published in the Journal of Medical Internet Research in November 2024 examined semaglutide products purchased from online sellers operating without prescription requirements.

Researchers evaluated product labeling, chemical composition, and microbiological characteristics.

Three lyophilized semaglutide samples were successfully obtained and analyzed.

Although the vendors advertised purity of approximately 99%, the researchers reported substantially lower measured semaglutide concentrations relative to the total powder mass.

What the Researchers Found

The study also reported that the measured semaglutide quantities exceeded the labeled amounts by approximately 29% to 39%.

Endotoxin was detected in all three samples, although viable microorganisms were not detected under the study's testing conditions.

These findings raised concerns about product labeling, composition, and quality controls within the specific unregulated online market investigated.

An important analytical distinction: The study's reported 7.7%–14.37% figures reflect the measured semaglutide fraction of the total lyophilized powder. They should not be directly equated with HPLC chromatographic peak-area purity. The researchers did not identify peptide-like impurities in their chromatographic assessment.

This distinction matters because lyophilized products may contain excipients and other non-peptide components.

A high chromatographic purity percentage does not necessarily mean that the entire powder mass consists of the target peptide.

Scientific reference: Ashraf et al., Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription, Journal of Medical Internet Research, 2024. Read the study.

Why 99% Peptide Purity Does Not Tell the Entire Story

Within the research peptide industry, 99% purity is frequently presented as a key quality indicator.

However, the significance of this percentage depends on the analytical method used.

A reported 99% HPLC area-purity result generally indicates that the principal peptide peak accounts for approximately 99% of the integrated chromatographic response under a particular method.

It does not, by itself, establish:

• The absolute mass of target peptide in the vial
• The absence of bacterial endotoxins
• Sterility
• The absence of residual solvents or other contaminants
• Complete manufacturing traceability
• Suitability for human or veterinary administration

For example, a lyophilized formulation may contain a highly purified peptide alongside intentionally added excipients.

The peptide itself may produce a high chromatographic area-purity result while representing only a fraction of the total powder mass.

Researchers must therefore distinguish among peptide identity, chromatographic purity, net peptide content, and other relevant quality attributes.

Why Independent Laboratories Sometimes Report Different Purity Results

Another concern within peptide procurement is disagreement between analytical laboratories.

A sample might receive a purity result above 99% from one laboratory and a lower result from another.

Potential explanations include different chromatographic columns, separation conditions, UV detection wavelengths, peak integration practices, sample preparation procedures, and sample handling.

A method that resolves additional peptide-related impurities may report a lower main-peak area percentage than a method in which those components co-elute.

However, genuine differences in sample quality, degradation, or manufacturing consistency may also contribute.

A significant discrepancy should never be dismissed simply because another laboratory reported a higher result.

Instead, researchers should compare chromatograms, analytical methods, sample identifiers, and relevant method-performance information.

Independent verification is most meaningful when testing is supported by scientifically suitable methods and documented sample traceability.

Related guide: Why Peptide Purity Results Differ Between Independent Laboratories, a step-by-step look at HPLC methods, peak integration and investigating conflicting COAs.

Does Manufacturing in China Automatically Mean Lower Peptide Quality?

No.

China is a major participant in the global pharmaceutical and chemical manufacturing supply chain.

Manufacturing location alone does not establish whether a particular material meets its intended specifications.

Quality depends on factors including the manufacturer's controls, validated analytical procedures, impurity management, raw-material traceability, and the effectiveness of independent oversight.

The October 2026 inspection findings demonstrate serious deficiencies at specific facilities.

They do not justify applying those findings to every manufacturer in the country.

Likewise, the 2024 semaglutide study investigated a small sample of products obtained through particular online sellers. It does not establish the quality of all peptides exported from China or identify a universal industry-wide purity trend.

The appropriate response is evidence-based supplier qualification and material verification rather than assumptions based solely on country of origin.

What Research Peptide Buyers Should Evaluate

For research organizations sourcing peptide materials, procurement decisions should consider more than an advertised purity percentage.

Important factors include:

• Batch-specific analytical documentation. Testing records should be traceable to the material being supplied.
• Identity verification. Appropriate analytical techniques should support confirmation of the expected peptide.
• Purity methodology. Buyers should understand whether reported percentages reflect HPLC area normalization, a quantitative assay, or another measurement.
• Net peptide content. Where relevant, quantitative testing should establish the amount of target peptide present.
• Additional quality attributes. Endotoxin, moisture, residual solvents, and other tests may be relevant depending on the material and its intended research application.
• Discrepancy investigation. Suppliers should have a documented process for evaluating unexpected or conflicting analytical results.

A certificate of analysis is valuable, but its reliability depends on the sampling, methods, records, and quality system supporting it.

NuRev Sales and the Importance of Analytical Transparency

At NuRev Sales, we recognize that research peptide procurement requires more than reliance on a single numerical purity claim.

Our emphasis is on the scientific interpretation of analytical documentation, material traceability, and the value of independent verification.

We believe that significant differences between laboratory findings should prompt appropriate technical review rather than assumptions about the accuracy of any individual report.

As scrutiny of international peptide supply chains increases, transparent documentation and scientifically justified quality assessment will remain essential considerations for research procurement.

Frequently Asked Questions

Conclusion: The Future of Peptide Quality Depends on Verification, Not Marketing Claims

Recent investigative reporting and peer-reviewed research have brought renewed attention to peptide manufacturing quality and the limitations of advertised purity percentages.

The evidence does not establish that China has adopted a policy to deliberately lower peptide purity standards.

It does demonstrate why researchers should critically evaluate analytical claims, verify material documentation, and understand the difference between chromatographic purity and actual peptide content.

A 99% purity claim is a measurement to evaluate—not a substitute for comprehensive quality assessment.

For research organizations, the strongest procurement decisions are informed by reliable documentation, appropriate testing, and transparent investigation of unexpected findings.

References

1. Los Angeles Times/Bloomberg. Black Mold, Bugs Found at Chinese Plants Making GLP-1 Compounding Agents. October 19, 2026.
2. Los Angeles Times. Unregulated Use of Peptides Raises Alarm Among Researchers. August 6, 2026.
3. Ashraf AR, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. Journal of Medical Internet Research. 2024;26:e65440.
4. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures.
5. U.S. Food and Drug Administration. Q14 Analytical Procedure Development.

Research Use Notice: This article is intended for scientific and educational purposes. It does not certify any specific manufacturer, batch, or laboratory. Research materials are not intended for human or veterinary administration. References to FDA guidance do not imply FDA approval or endorsement of NuRev Sales.